Home
Product
Antibody
Biosimilar Antibodies
CFD (lampalizumab Biosimilar) Recombinant Monoclonal Antibody

CFD (lampalizumab Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA005271MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P00746

Alternative Names

Complement factor D；EC 3.4.21.46；Adipsin；C3 convertase activator；Properdin factor D , CFD, DF PFD

Species Reactivity

Human

Immunogen

Recombinant Human CFD protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

In stock
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is designed as a research-grade biosimilar to lampalizumab, targeting complement factor D (CFD), a highly specific serine protease that plays a critical role in the alternative complement pathway. CFD, also known as adipsin, cleaves factor B when bound to C3b, generating the C3 convertase complex that amplifies complement activation. This protein is constitutively active in plasma and represents the rate-limiting enzyme of the alternative pathway, making it a strategic target for complement-mediated inflammatory conditions. CFD dysregulation has been implicated in age-related macular degeneration (AMD), particularly geographic atrophy, as well as other complement-associated pathological processes including certain kidney diseases and inflammatory disorders.

Lampalizumab was developed as a therapeutic Fab fragment specifically designed to inhibit CFD activity and reduce complement-mediated tissue damage in dry AMD. This biosimilar antibody provides researchers with a valuable tool for investigating complement pathway mechanisms, exploring CFD's role in retinal degeneration and inflammatory disease models, and conducting preclinical studies related to complement inhibition strategies. It supports investigations into complement biology and potential therapeutic interventions targeting the alternative pathway.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Its function is homologous to that of C1s in the classical pathway.

Gene References into Functions

MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. PMID:27535802
disturbance of reciprocal relationships between adipsin and leptin in obesity is associated with the development of insulin resistance PMID:28864895
TZDs (pioglitazone, rosiglitazone, and ciglitazone) slow tumor cell growth in vitro and in vivo with decreases in cell proliferation and increases in PPARg and adipsin PMID:28219679
The strong association of PLIN1, CFD and ADIPOQ genes with adipogenesis prompted authors to study the influence the bone health status as evaluated by quantitative ultrasound (QUS) bone densitometer in a North Indian cohort. Overall, ADIPOQ (rs1501299 and rs3774261) and combined cluster of PLIN1 rs2304796 and rs2304795) and CFD (rs1683563) demonstrated correlation. PMID:28189761
our findings set up a novel mechanism for FABP4, adipsin and adiponectin through gut microbiota mediating expression in gut Paneth cells. PMID:26687459
Overall adipsin levels among male asbestos industry workers were significantly higher than among control subjects. PMID:25840635
Data indicate that a urinary protein, adipsin, was significantly increased in patients with preeclampsia. PMID:24958499
Study demonstrates that T2DM patients with beta cell failure are deficient in adipsin. PMID:24995977
Complement factor D (FD) is activated by its substrate through interactions outside the active site which lock the unbound native state into an ordered inactive conformation via the self-inhibitory loop in FD. PMID:24598742
We demonstrate novel secretion of adipsin and ASP by placental Hofbauer cells. PMID:23956345
Increased activation of the alternative complement pathway in vitreous was controlled by disease stage and genetic variation in the complement pathway, supporting a role for complement activation in macular degeneration disease pathogenesis. PMID:22930722
Anti factor D Fab fragment inhibits FD proteolytic function by interfering with macromolecular substrate access rather than by inhibiting FD catalysis. PMID:22362762
CFD regulates activation of the alternative complement pathway, which is implicated in age related macular degeneration pathogenesis. PMID:22003108
CFD may not play a major role in the genetic susceptibility to age-related macular degeneration. PMID:21139680
crystal structure of C3bB at 4 A and complex with factor D at 3.5 A; data show how factor B binding to C3b forms open "activation" state of C3bB; Factor D binds open conformation of factor B through a site distant from the catalytic center PMID:21205667
As adiponectin and adipsin levels in CSF did not correlate with their levels in plasma, it seems that there could be a secondary intrathecal synthesis of these adipocytokines in multiple sclerosis PMID:19538214
increased serum levels in patients with seasonal allergic rhinitis PMID:19699327